Research across Cancer
Related studies from across the Cancer family.
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Meta-analysis links baseline and dynamic ctDNA to survival in advanced NSCLC
ctDNA in blood predicts survival in advanced lung cancer
This systematic review and meta-analysis of 43 studies found that detectable or elevated baseline plasma ctDNA was associated with worse ove…
A blood test for tumor DNA can predict survival in advanced lung cancer, helping guide treatment decisions.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Narrative review outlines multimodal decision-making for EGFR-mutant NSCLC with leptomeningeal metastasis
Doctors outline a pathway for treating lung cancer that spreads to the brain
This narrative review addresses patients with EGFR-mutant non-small cell lung cancer who develop resistance to tyrosine kinase inhibitors an…
This review outlines a clinical pathway to help physicians personalize treatment for lung cancer patients with brain spread.
Case report on ivonescimab for EGFR-TKI-resistant lung adenocarcinoma with pericardial effusion
One Drug Shrinks Lung Tumors When Others Stop Working
This is a case report and literature review of a 77-year-old female with EGFR-TKI-resistant advanced lung adenocarcinoma and malignant peric…
A 77-year-old woman with advanced lung cancer saw her tumors shrink and dangerous fluid around her heart disappear after trying a new drug c…
Network meta-analysis reveals induction immunochemotherapy plus CCRT improves survival for unresectable esophageal cancer patients compared to CCRT alone
Immunotherapy combinations show promise for hard-to-treat esophageal cancer
A comprehensive network meta-analysis of 9,648 patients indicates that induction immunochemotherapy followed by concurrent chemoradiotherapy…
Adding immunotherapy to standard treatment may help people with advanced esophageal cancer live longer, according to a new analysis of many …
Post hoc reanalysis suggests stereotactic radiotherapy may improve local control in medically inoperable Stage I non-small cell lung cancer
New analysis gives hope for early lung cancer patients who cannot have surgery
This post hoc Bayesian reanalysis of the LUSTRE trial evaluated stereotactic radiotherapy versus conventional radiotherapy in medically inop…
A new statistical review suggests a focused radiation approach may better control early lung cancer for patients who cannot undergo surgery.
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…
Toripalimab plus anlotinib maintenance shows promise in ES-SCLC after first-line chemo
New combo therapy extends life for advanced small cell lung cancer patients
This multi-center, single-arm phase II trial evaluated maintenance toripalimab plus anlotinib in 20 patients with extensive-stage small cell…
A new drug pair extends life for advanced lung cancer patients by changing how their immune system fights back
Meta-analysis shows platinum-etoposide plus PD-1/PD-L1 inhibitor improves survival in extensive-stage small-cell lung cancer
Adding PD-1 or PD-L1 inhibitors improves survival for extensive-stage small-cell lung cancer
This meta-analysis of phase III trials evaluated platinum-etoposide combined with a PD-1 or PD-L1 inhibitor versus platinum-etoposide alone …
Adding a PD-1 or PD-L1 inhibitor to standard chemotherapy improves survival for extensive-stage small-cell lung cancer without increasing se…
Ultrasound-guided salvage brachytherapy with interstitial hyperthermia shows low toxicity in locally recurrent prostate cancer
New prostate cancer treatment shows low side effects after 5 years
This prospective phase 2 trial evaluated ultrasound-guided salvage brachytherapy with interstitial hyperthermia in 109 patients with locally…
A new treatment for recurrent prostate cancer kept 93% of patients alive at 5 years with very low serious side effects.
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not